Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

Conditions

• Hemophagocytic Lymphohistiocytosis

Eligibility Criteria

Sex

ALL

Age

3 Months - 25 Years

Healthy Volunteers

Not accepted

Interventions

• tocilizumab — DRUG
  single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.

Study Details

This study seeks to determine the efficacy of tocilizumab (TCZ) in patients with hemophagocytic lymphohistiocytosis (HLH) and high cytokine levels (proteins involved in inflammation) in an attempt to decrease the damage caused by these proteins; and secondarily to assess its safety and impact on disease activity.

Key Dates

Start date

Dec 31, 2013

Status verified

Mar 2022

Primary completion

May 31, 2021

Completion

May 31, 2021

Study Design

Enrollment

0 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: treatment
  single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.

Primary Outcome Measure

Reduction in serum interferon-gamma levels after tocilizumab (TCZ) administration [ Time Frame: baseline, 24 -36 hours, and 4-7 days after administration of TCZ ]

Locations (1)

Find similar trials in Philadelphia, PA

Related Studies

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
  Recruiting · Sanford Health · Sioux Falls, South Dakota